{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.8","upperLimit":"93.9","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"ClinRO measure for EL hair loss is comprised of 4 category response options: 0 = The EL form a continuous line along the eyelids on both eyes; 1 = There are minimal gaps and the EL are evenly spaced along the eyelids on both eyes; 2 = There are significant gaps along the eyelids or the EL are not evenly spaced along the eyelids; 3 = No notable EL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who received one 4 mg Baricitinib tablet administered orally QD.","id":"OG000","title":"4 mg Baricitinib Phase 3 Open-Label Addendum"}],"paramType":"NUMBER","populationDescription":"All randomized phase 3 open-label addendum participants with baseline ClinRO measure for EL hair loss ≥ 2 and who had evaluable data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Week 52","title":"Percentage of Participants Achieving ClinRO Measure for Eyelash (EL) Hair Loss 0 or 1 With ≥ 2-point Improvement From Baseline (Among Participants With ClinRO Measure for EL Hair Loss ≥ 2 at Baseline) - Phase 3 Open-Label Addendum","type":"SECONDARY","unitOfMeasure":"percentage of participants"}